Prevention of venous thromboembolism in medically ill patients: A clinical update

Postgraduate Medical Journal

Volumn 82, Issue 974, 2006, Pages 806-809

  Turpie, Alexander G G ^a,b   Leizorovicz, Alain ^c  

^a HAMILTON GENERAL HOSPITAL   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; COMPRESSION; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; HOSPITAL PATIENT; HUMAN; LUNG EMBOLISM; META ANALYSIS; MORBIDITY; MORTALITY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ANTICOAGULANTS; CHRONIC DISEASE; CLINICAL TRIALS; HOSPITALIZATION; HUMANS; PRACTICE GUIDELINES; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33846254497     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2005.044107     Document Type: Review

References (37)

1. Cohen AT. Discoveries in thrombosis care for medical patients. Semin Thromb Hemost 2002;28(Suppl 3):13-17.
2. Cohen AT, Alikhan R. Prophylaxis of venous thromboembolism in medical patients. Curr Opin Pulm Med 2001;7:332-7.
3. Thromboembolic Risk Factors (THRiFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992;305:567-74.
4. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10:448-50.
5. Oger E, Bressollette L, Nonent M, et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost 2002;88:592-7.
6. Geerts W, Cook D, Selby R, et al. Venous thromboembolism and its prevention in critical care. J Crit Care 2002;17:95-104.
7. Cohen AT, Edmonson RA, Phillips MJ, et al. The changing pattern of venous thromboembolic disease. Haemostasis 1996;26:65-71.
8. Michota FA. Venous thromboembolism prophylaxis in the medically ill patient. Clin Chest Med 2003;24:93-101.
9. Enders JM, Burke JM, Dobesh PP. Prevention of venous thromboembolism in acute medical illness. Pharmacotherapy 2002;22:1564-78.
10. Haas SK. Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost 2002;28:577-83.
11. Ageno W, Squizzato A, Ambrosini F, et al. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 2002;87:746-50.
12. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 2001;120:1964-71.
13. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004;93:259-62.
14. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9.
15. Samama MM, Cohen AT, Darmon J-Y, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.
16. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism - a population-based case-control study. Arch Intern Med 2000;160:809-15.
17. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-20.
18. Hansson P-O, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-74.
19. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl):338S-400S.
20. Turpie AG. Low-molecular-weight heparins and unstable angina - current perspectives. Haemostasis 1997;27(Suppl 1):19-24.
21. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005;365:1163-74.
22. Kakkar AK, Williamson RCN. Prevention of venous thromboembolism in cancer using low-molecular-weight heparins. Haemostasis 1997;27:32-7.
23. Heit JA. Prevention of venous thromboembolism. Clin Geriatr Med 2001;17:71-92.
24. Jacobs LG. Prophylactic anticoagulation for venous thromboembolic disease in geriatric patients. J Am Geriatr Soc 2003;51:1472-8.
25. Amaragiri S, Lees T. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2003;(4). Cochrane Library. Issue 1. Oxford: Update Software, 2002.
26. Devlin JW. The role of low molecular weight heparin for DVT prophylaxis in acutely ill medical patients. J Inform Pharmacother 2000;3:300-8.
27. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14-19.
28. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safely. Chest 1998;114(Suppl):489S-510S.
29. Bergmann JF, Caulin C. Heparin prophylaxis in bedridden patients. Lancet 1996;348:205-6.
30. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet 1996;347:1357-61.
31. Vaitkus PT, Leizorovicz A, Goldhaber SZ. Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vasc Med 2002;7:269-73.
32. Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonographv in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998;129:1044-9.
33. Kearon C, Julian JA, Newman TE, et al. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 1998;128:663-77.
34. Vaitkus PT, Leizorovicz A, Cohen AT, et al. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 2005;93:76-9.
35. Fareed J, Hoppensteadt D, Jeske W, et al. The available low molecular weight heparins are not the same. Clin Appl Thromb Hemost 1997;3(Suppl 1):S38-52.
36. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325-9.
37. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005;352:969-77.